Search

Displaying results 3571 - 3580 of 10000 in total
  1. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    [A253707] In February 2015, vonoprazan was first marketed in Japan for the treatment of acid-related disorders and as an adjunct to _Helicobacter pylori_ (_H. pylori_) eradication. … PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.

  2. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.

  3. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    [L41860] It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.[A248775] … [L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.

    Categories: Prostaglandins I
  4. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15710
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Fluarix Tetra Injektionssuspension in einer Fertigspritze
  5. Drug

    Ospemifene

    go.drugbank.com/drugs/DB04938
    Approved

    Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

    Categories: Selective Estrogen Receptor Modulators
  6. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    It is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier

  7. Target

    Prostaglandin E2 Receptors

    go.drugbank.com/bio_entities/BE0010100
    TargetHumans

    Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. … Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system.

    Polypeptides: Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP2 subtypeSynonyms: PGE receptor EP1 subtype, Prostanoid EP1 receptor
  8. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It was patented and manufactured by a French pharmaceutical company Servier.

    Categories: Drugs Used in Diabetes
  9. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.

  10. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … [L45469] In February 2023, Kinnate Biopharma received Fast Track designation from the FDA for KIN-3248 to treat unresectable, locally advanced or metastatic cholangiocarcinoma (CCA).[L45474]